Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

Leukemia

Volumn 17, Issue 1, 2003, Pages 211-219

  van de Donk, N W C J ^a   Kamphuis, M M J ^a   van Dijk, M ^a   Borst, H P E ^a   Bloem, A C ^a   Lokhorst, H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antisense oligodeoxynucleotide; Bcl 2; Chemosensitization; Drug resistance; Multiple myeloma

Indexed keywords

ALPHA ACTIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CARBOXYFLUORESCEIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; MESSENGER RNA; OBLIMERSEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

AGED; APOPTOSIS; ARTICLE; CELL LABELING; CELL NUCLEUS; CHEMOSENSITIVITY; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0037265811     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402768     Document Type: Article

References (64)

1. Dalton WS, Jove R. Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol 1999; 26 (5 Suppl. 13): 23-27.
2. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913-917.
3. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 1992; 340: 255-259.
4. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-495.
5. Raaijmakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029-1036.
6. Filipits M, Drach J, Pohl G, Schuster J, Stranzl T, Ackermann J, Konigsberg R, Kaufmann H, Gisslinger H, Huber H, Ludwig H, Pirker R. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999; 5: 2426-2430.
7. Linsenmeyer ME, Jefferson S, Wolf M, Matthews JP, Board PG, Woodcock DM. Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992; 65: 471-475.
8. Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992; 79: 213-222.
9. Ishikawa H, Kawano MM, Okada K, Tanaka H, Tanabe O, Sakai A, Asaoku H, Iwato K, Nobuyoshi M, Kuramoto A. Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol 1993; 83: 68-74.
10. Krett NL, Pillay S, Moalli PA, Greipla PR, Rosen ST. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res 1995; 55: 2727-2729.
11. Futscher BW, Foley NE, Gleason-Guzman MC, Meltzer PS, Sullivan DM, Dalton WS. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 1996; 66: 520-525.
12. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel MT, Garrido C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 2000; 14: 1833-1849.
13. O'Gorman DM, Cotter TG. Molecular signals in anti-apoptotic survival pathways. Leukemia 2001; 15: 21-34.
14. Hardin J, MacLeod S, Crigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84: 3063-3070.
15. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162: 248-255.
16. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood 2000; 96: 3175-3180.
17. Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, Dalla-Favera R. Ras oncogene mutation in multiple myeloma. J Exp Med 1989; 170: 1715-1725.
18. Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res 1997; 57: 2268-2275.
19. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998; 26: 597-603.
20. Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia 2001; 15: 264-271.
21. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR: role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
22. Gauthier ER, Piche L, Lemieux G, Lemieux R. Role of bcl-X(L)in the control of apoptosis in murine myeloma cells. Cancer Res 1996; 56: 1451-1456.
23. Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J, Vescio R, Rettig M, Berenson J, Krajewski S, Reed JC, Lichtenstein A. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998; 58: 256-262.
24. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885-1893.
25. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-199.
26. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996; 88: 1805-1812.
27. Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 1998; 13: 397-405.
28. Hamilton MS, Barker HF, Ball J, Drew M, Abbot SD, Franklin IM. Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia 1991; 5: 768-771.
29. Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, Nilsson K. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992; 79: 495-502.
30. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, Mellstedt H, Einhorn S. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995; 63: 190-192.
31. Ong F, van Nieuwkoop JA, Groot-Swings GM, Hermans J, Harvey MS, Kluin PM, Kluin-Nelemans JC. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995; 9: 1282-1284.
32. Harada N, Hata H, Yoshida M, Soniki T, Nagasaki A, Kuribayashi N, Kimura T, Matsuzaki H, Mitsuya H. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 1998; 12: 1817-1820.
33. Puthier D, Pellat-Deceunynck C, Barille S, Robillard N, Rapp MJ, Juge-Morineau N, Harousseau JL, Bataille R, Amiot M. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999; 13: 289-294.
34. Renner S, Weisz J, Krajewski S, Krajewska M, Reed JC, Lichtenstein A. Expression of BAX in plasma cell dyscrasias. Clin Cancer Res 2000; 6: 2371-2380.
35. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
36. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-519.
37. Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995; 55: 2262-2265.
38. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-736.
39. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994; 84: 595-600.
40. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-3055.
41. Pepper C, Thomas A, Hoy T, Cotter F, Bentley P. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107: 611-615.
42. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999; 59: 4030-4034.
43. Schlagbauer-Wadl H, Klosner C, Heere-Ress E, Waltering S, Moll I, Wolff K, Pehamberger H, Jansen B. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 2000; 114: 725-730.
44. Guinness ME, Kenney JL, Reiss M, Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res 2000; 60: 5354-5358.
45. Tortora G, Caputo R, Damiano V, Bianco R, Fontanini C, Cuccato S, De Placido S, Bianco AR, Ciardiello F. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res 2001; 7: 2537-2544.
46. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998; 78: 1035-1042.
47. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4: 232-234.
48. Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 1999; 54 (6A Suppl.): 36-46.
49. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, Lopez-Berestein C, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000; 95: 3929-3938.
50. Klasa RJ, Bally MB, Ng R, Goldie JH, Cascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000; 6: 2492-2500.
51. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer ED. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide C3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000; 6: 2891-2902.
52. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-1141.
53. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
54. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728-1733.
55. Jego C, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, Harousseau JL, Bataille R, Pellat-Deceunynck C. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94: 701-712.
56. Haigler HT, Maxfield FR, Willingham MC, Pastan I. Dansylcadaverine inhibits internalization of 1251-epidermal growth factor in BALB 3T3 cells. J Biol Chem 1980; 255: 1239-1241.
57. Roovers DJ, van Vliet M, Bloem AC, Lokhorst HM. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 1999; 23: 539-548.
58. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16: 1362-1371.
59. Koziolkiewicz M, Gendaszewska E, Maszewska M, Stein CA, Stec WJ. The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase. Blood 2001; 98: 995-1002.
60. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-1845.
61. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 1998; 160: 5898-5906.
62. Stein CA. Does antisense exist? Nat Med 1995; 1: 1119-1121.
63. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995; 93: 1814-1823.
64. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13: 300-309.